

Aseptic Processing Summit 2026

Best Practice Technologies for Aseptic Processing
and Contamination Control

December 2-3, 2026, Sheraton La Jolla, CA

Featuring Lessons Learned & Case Studies from Industry Experts:



Jürgen Metzger
PharmaTech Consulting



Marsha Steed
Steed Microbio



Stephen Yang
Merck



James Hathcock
Cytiva



Birte Scharf
Franz Ziel GmbH



Jim Polarine
STERIS



Derek Duncan
Lighthouse Instruments



Klaus Ullherr
Syntegon GmbH



Amanda Curtis
ValSource



Meg Provenzano
Veolia



Tim Cser
MilliporeSigma



Elizabeth Massoth
CURIS



Allison Scott
BWT Pharma & Biotech, Inc.



Mark Hallworth
Particle Measuring Systems



Josh Russell
AST Inc.



Jeff Woodson
CURIS



Sebastian Scheler
Innerspace



Mitch Garber
MG Aseptic & QA Consulting



Noël Long
Cytiva

With Comprehensive Coverage On:

- FDA Warning Letters: Root Cause Analysis and Technology Enablers in Aseptic Manufacturing
- Reducing Glove Interventions in Aseptic Manufacturing: Challenges and Benefits
- Advancing Fill-Finish with Digital Twin Technology
- Flexible Fill/Finish Solutions for Ready-to-Use Containers
- Using Environmental Monitoring Data as an Indicator of Aseptic Process Quality
- Advances in Rapid EM and Continuous Monitoring in Cleanrooms and Controlled Environments
- Techniques for Monitoring Robotic Filling Machines
- Testing and Control Strategies for Container Closure Integrity
- Ensuring First Air Integrity in Aseptic Manufacturing
- Applying New Industry Guidance on Designing a Robust Disinfectant Field Trial
- Annex 1 CCS—Lessons Learned
- Innovations Shaping Bio-decontamination in Material Transfer Environments
- Case Study in Applying the ANSI-03 Quality Risk Management Standard
- Transforming Quality Risk Management for Faster Commercialization
- And More!

With Representation From:



Contact: Kim Hubbard

khubbard@pharmaedresources.com or call (217) 721-5774

PharmaEd Resources, Inc. • 2810 Robeson Park Drive • Champaign, IL 61822
tel. 217.721.5774 • web. www.pharmaedresources.com

Aseptic Processing Summit 2026

Sponsored By:



Wednesday, December 2, 2026

7:30 *Registration Check-in & Complimentary Breakfast*

8:25 *Chairperson Marsha Steed's Welcome & Opening Remarks*
Marsha Steed, Founder and CEO, Steed MicroBio LLC



Spotlight on Environmental Monitoring

8:30 **How to Use Environmental Monitoring Data as an Indicator of Aseptic Process Quality**

Amanda Curtis, Microbiology Consultant, ValSource



As the understanding of aseptic manufacturing continues to evolve, it's increasingly clear that assessing the quality of aseptically manufactured products requires the integration of data from multiple sources. In-process bioburden testing, finished product sterility testing, process validation (including media fills), and environmental monitoring (EM) are each limited on their own; when considered together, they provide critical insight into the holistic state of control of both the process and facility, as well as overall product quality.

One key area of this challenge lies in effectively leveraging the vast amount of EM data generated during production. How can this data be efficiently interpreted and translated into action? What are its strengths and limitations? And what do excursions (or the dreaded "adverse trend") truly indicate about the state of control or the product batch in question?

This presentation will explore these questions and offer practical guidance on how both the EM/Microbiology and Aseptic Processing teams can use EM data to gain a clearer understanding of process performance and product quality. A case study will illustrate how an adverse trend can be communicated effectively to stakeholders, and how such insights can inform product impact assessments and next steps.

9:10 **What's New in Rapid EM and Continuous Monitoring in Cleanrooms and Controlled Environments**

Tim Cser, Senior Technology Specialist, MilliporeSigma



The world of active, viable sampling has evolved quickly over the last few years with the implementation of EU Annex 1 and the introduction of new technologies. With newer technologies such as biofluorescent viable and non-viable counting, "continuous monitoring" and a revised data integrity focus, firms have more variables than ever in designing and testing their clean spaces. This presentation will explain the latest

advancements and expectations in the active, viable monitoring world.

10:50 **Innovation in Continuous Monitoring—Online Water Bioburden Analyzer Technologies and Implementation Case Study**

Allison Scott, Principal Scientist, BWT Pharma & Biotech, Inc.



Multiple Online Water Bioburden Analyzers are now available that support the online monitoring of bioburden in pharmaceutical water systems. Pharmaceutical water bioburden monitoring has historically relied on point of use sampling and culture-based testing—methods that are labor-intensive and provide retrospective results. Today, advanced online water bioburden analyzers support real or near-real-time monitoring of bioburden within pharmaceutical water systems through the detection of intrinsic or extrinsic fluorescence instead of growth. These systems provide a rich dataset for trending due to more frequent sampling and support proactive process monitoring and in-process control applications. Key objectives include providing an overview of available online water bioburden analyzer technologies and an implementation case study including establishing alert and action levels and trending rules.

10:30 *Mid-morning Coffee & Networking Break*

Regulatory Spotlight—What FDA Warning Letters Reveal in Aseptic Manufacturing

11:00 **FDA Warning Letters: Root Cause Analysis and Technology Enablers in Aseptic Manufacturing**

Jürgen M. Metzger, CEO, Pharma-Technology Consulting, LLC



Human interventions remain one of the most persistent sources of contamination risk and operational variability in aseptic manufacturing. Despite widespread adoption of isolator technology, glove interventions continue to contribute significantly to deviations, with industry data indicating that up to 50% of quality events are linked to human error.

This presentation examines the residual risks associated with glove-based interventions from a microbiological, engineering, and regulatory perspective, including their impact on first air principles, airflow disruption, and contamination pathways. Current expectations from EU GMP Annex 1 and FDA guidance are discussed, emphasizing the increasing regulatory focus on minimizing or eliminating human interaction.

Real-world case studies from Lonza and Biogen illustrate how Human Performance (HuP) programs can significantly reduce deviations by shifting focus from individual error to system design. Building on this, the presentation introduces gloveless aseptic processing platforms as a next-generation solution, integrating robotics, sensors,

and vision systems to eliminate manual interventions entirely.

Attendees will gain insight into how advanced technologies, combined with system-centric design principles, can enhance sterility assurance, improve operational resilience, and support evolving manufacturing demands such as ATMPs and personalized therapies.

11:40 Merck Presentation



Stephen Yang, Director in Global Quality—Microbial Control and Sterility Assurance, Merck & Co.

Abstract Coming Soon

12:20 Complimentary Lunch

Going Gloveless

1:30 Flexible Fill/Finish Solutions for Ready-to-Use Containers – From Classic to Gloveless



Klaus Ullherr, Senior Product Manager SPM-PHL, Syntegon Technology GmbH

This presentation will trace the journey from flexible nest filling with statistical and 100% IPC to completely gloveless systems. Key topics to be covered include:

- Case study: The seamless integration of a state-of-the-art fill finish solution within an existing production environment
- Packstyle flexibility, enabling rapid adaptation to changing market requirements
- No-touch-transfer system ensuring sterility and contamination control
- 100% in-process checkweighing (IPC) enhancing product quality and compliance
- Peristaltic pump with single-use filling systems
- Integration of in-air isolator
- Implementation of Annex 1 requirements in practice
- CFD and smoke studies
- Use of different robotics solutions
- Gloveless working cell for small batches
- Fully aseptic set-up of the machine

And finally, a sneak peek into the future: A breakthrough in next-generation aseptic fill/finish production.

2:10

Advancing Sterility Assurance Through Biofluorescent Particle Counting in Closed, Gloveless Robotic Aseptic Filling Platforms



James Hathcock, Principal Director of Regulatory and Validation Strategy, Cytiva

Aseptic filling in pharmaceutical manufacturing can be challenging, with contamination risks and scalability constraints risking time to market for delivering life-changing therapeutics. Standardized and scalable platform approaches employing state-of-the-art gloveless, robotic filling technologies coupled with real-time environmental monitoring can improve process understanding, strengthen sterility assurance, eliminate interventions, and accelerate time to market. This presentation will share lessons learned from computational fluid dynamics (CFD) modeling and airflow visualization studies using neutrally buoyant smoke to optimize airflow design and environmental monitoring (EM) sampling locations within standardized aseptic filling platforms. In addition, a practical roadmap for implementing biofluorescent particle counting (BFPC) for Grade A environmental monitoring will be presented, including experiences with baseline establishment, interference assessments, and approaches for demonstrating that the manufacturing process remains in a validated state of control. This standardized modular approach strengthens process understanding and control, while minimizing additional validation for end-users, thereby accelerating time to GMP inspection approval and time to market.

2:50

Afternoon Snack & Networking Break

Technology Spotlight—Digital Twin & Robotics Applications

3:20

Advancing Fill-Finish with Digital Twin Technology



Josh Russell, Vice President of Technical Sales, AST

As pharmaceutical manufacturers are looking to navigate and excel in Pharma 4.0, a key aspect of the digitization breakthrough is the advent and exploration of digital twin technology. Digital twin is a dynamic, predictive virtual model that synthesizes real-time data, physical operations, and virtual environments in an exact digital replica of a machine, system, or complete manufacturing operation. A natural part of progress within any industry is the transition from one technological paradigm to the next, and, with the advent of solutions like digital twin, a host of opportunities and questions face drug product manufacturers. The innovative integration of the physical, digital, and data spaces offered by digital twin provides exciting possibilities for the production of liquid pharmaceuticals at every stage of drug development to commercial manufacturing. This presentation will provide an overview of the evolution of digital manufacturing solutions and Pharma 4.0, a primer on digital

twin technology, and what the industry can anticipate going into the future.

Highlights include:

- Definitions and principles of digital twin technology
- Three real-world use cases of digital twin for fill-finish
- An exploration of potential applications and benefits for drug product manufacturing, including time to market, process formulation, quality control, risk assessments, and predictive analytics

4:00

Monitoring of Robot Filling Machines

Mark Hallworth, Life Sciences GMP Advisor, Particle Measuring Systems



With the advancement of small batches and ATMP/CGT the use of glove-free isolators is becoming prevalent and robotics are used for the majority of material handling within the isolator. As glove ports were historically used for routine environmental monitoring, the absence of these gloves and operator interactions, require that the robot performs these functions. This session will look at the mechanisms being used in industry today, along with advancements in performing remote, traditional, microbiological sampling meeting the needs of regulatory guidance and providing speciation without additional constraints on the environment.

4:40

End of Day One

Thursday, December 3, 2026

7:30

Complimentary Breakfast

Spotlight on Container Closure Integrity

8:30

Testing and Control Strategies for Container Closure Integrity

Derek Duncan, Director Product Lines, LIGHTHOUSE Instruments



In response to the implementation of the revised EU GMP Annex 1 and the announced revision of the USP<1207> Package Integrity Evaluation—Sterile Products chapter, best practices for assuring container closure integrity have and will continue to evolve. In addition, the continued development of novel therapies (cell & gene therapies) as well as the increased use of complex delivery systems (autoinjectors, for example) have required new approaches for container closure integrity (CCI) testing. This presentation uses current case study examples of how companies are evolving best practices and defining approaches to comply with new container closure requirements. The case studies illustrate various topics and approaches including the validation of container closure integrity test methods for novel therapies and containers, generating CCI data in a product life cy-

cle approach, and the choice to perform 100% leak detection vs. sampling in commercial manufacturing.

9:10

Protective Airflow in Aseptic Manufacturing - Ensuring First Air Integrity

Dr. Birte Scharf, Senior Scientist GMP Compliance, Franz Ziel GmbH



Maintaining unidirectional airflow and protecting first air over critical process surfaces remain key aspects to Annex 1 compliant aseptic operations. In practice, this can be difficult whenever operator interventions or equipment design disrupt airflow patterns. Smoke studies are still the primary tool to demonstrate airflow performance, yet their usefulness depends greatly on how realistically they are designed, executed and interpreted. Therefore, Computational Fluid Dynamic Studies (CFDs) can be a very supportive tool to predict critical airflow patterns and mitigate risks already during design phase of Barrier Systems.

One recurring challenge is the need to manipulate Rapid Transfer Ports (RTPs) from inside the barrier system, which can impair First Air Protection above indirect product contact parts. Such situations underline how essential careful glove management strategies are and at the same time expose the inherent limitations of gloved operations for contamination control.

To address these risks, several approaches are gaining importance, such as reducing glove use and moving towards equipment designs that avoid glove reach above critical surfaces, including gloveless technologies. These developments show how airflow design, human factors, and equipment innovation must be considered together in order to achieve contamination control that align with Annex 1 expectations.

Controlling Bioburden Through a Robust CCS

9:50

Case Study: New Industry Guidance on Designing a Robust Disinfectant Field Trial

Jim Polarine, Jr., MA, Principal Consultant, STERIS Corporation



This case study utilized a ready to use quaternary ammonium disinfectant and a hydrogen peroxide/peracetic acid sporicide to control bioburden in a new cleanroom operation post construction. Material flow, engineering controls, utility supplies, and operational procedures will be discussed. This presentation will cover new details such as witnessing activities during a disinfectant field trial from the new PDA Technical Report #70. In depth, field trial environmental monitoring data will be covered. This CCS case study has recently been published in Cleanroom Technology Europe.

10:30 *Midmorning Coffee & Networking Break***Spotlight on Annex 1**11:00 **Modernizing Endotoxin Testing within the EU GMP Annex 1 Contamination Control Strategy***Meg Provenzano, Global Product Manager for Endotoxin, Veolia*

With the formal finalization of EU GMP Annex 1, pharmaceutical manufacturers are mandated to design and implement a holistic, lifecycle-based Contamination Control Strategy (CCS). A central pillar of any sterile manufacturing CCS is the rigorous control and monitoring of bacterial endotoxins across critical utilities (such as Water for Injection), raw materials, in-process steps, and finished parenteral products. Furthermore, Annex 1 explicitly encourages the adoption of scientifically sound, modern, and innovative technologies to streamline processes, minimize human error, and enhance sterility assurance.

Traditionally, Bacterial Endotoxins Testing (BET) has relied on manual, operator-dependent methods that are highly susceptible to analyst technique variations, accounting for the vast majority of out-of-specification (OOS) deviations and high invalid retest rates (historically 5% to 10%). Moreover, legacy LAL assays consume large volumes of natural horseshoe crab resources, posing supply chain and ecological vulnerabilities.

This presentation outlines a modern, fully compliant framework for integrating automated centripetal microfluidics and recombinant Cascade Reagents (rCR) into a site's CCS. By transitioning to a microfluidic platform, laboratories can automate the fluidic measuring, splitting, and mixing of samples and reagent.

This session will detail:

- **Alignment with Annex 1 & Quality Risk Management (QRM):** Establishing endotoxin control points across the product lifecycle.
- **Microfluidic Compliance:** Ensuring data integrity (ALCOA+) and pharmacopeial compliance by executing a live 3- to 5-point standard curve in triplicate contemporaneous with every single assay, maintaining a <2% invalid rate.
- **Validation and Recombinant Migration Pathways:** Streamlining the transition from traditional LAL to rCR via direct comparison studies and 3-lot alternative method validations.

By combining microfluidic automation with recombinant biochemistry, not only is the core regulatory intent of Annex 1 met, but attendees will see how an historically volatile manual assay is transformed into an automated, highly robust, and ecologically sustainable control point.

Key Learning Objectives for Attendees:

- Understand the regulatory mandates of EU GMP Annex 1 regarding holistic Contamination Control Strategies (CCS)
- Learn how the implementation of modern, rapid microbiological methods achieve Annex 1 compliance.
- Evaluate the biochemical differences and recovery equivalencies between traditional LAL, single-protein recombinant Factor C (rFC), and full-cascade recombinant Cascade Reagents (rCR).
- Quantify the operational, financial, and data integrity advantages of microfluidic automation
- Formulate a structured validation roadmap for transitioning water loops and product matrices from manual gel-clot or kinetic assays to microfluidic-based rCR under USP <86> guideline

Critical Issues—Material Transfer

11:40

From Efficiency to Efficacy: Innovations Shaping Bio-decontamination in Transfer Environments*Beth Massoth, Biocontainment Specialist CURIS & Jeff Woodson, VP of Revenue Operations, CURIS*

As use of automated biodecontamination continues to expand, pharmaceutical manufacturers' concerns about challenges associated with traditional methods, such as material degradation, prolonged aeration times, and staff safety have grown, as well. This presentation covers the latest breakthroughs in integrated biodecontamination systems for material transfer environments in pharmaceutical and research facilities. Drawing from studies conducted at pharmaceutical manufacturing locations across the US, we will explore the implementation of novel systems in both upstream and downstream transfer spaces, with a focus on their ability to maintain efficacy without compromising staff safety or compatibility with sensitive equipment or materials.

The discussion will include:

- A review of microbial decontamination challenges in different use cases for pharmaceutical and research facilities.
- Results from the automated system's operation, including cycle times, microbial efficacy, and material impact.
- Best practices for implementing an integrated biodecontamination system for transfer spaces.

The studies highlight the potential for integrated systems to streamline operations, minimize contamination risks, and provide a consistent, reliable solution for biodecontamination. By presenting real-world data, this session aims to provide facility managers, quality engineers, pro-

cess engineers, and operational leaders with practical insights into optimizing biodecontamination strategies in aseptic environments.

12:20 *Complimentary Lunch*

1:30 Improving Materials Movement into Cleanrooms—Reducing Risk



Mitch Garber, President, MG Aseptic and Quality Assurance Consulting

Controls in the cleanroom environment for sterile and aseptically processed medicines must be suitable to reduce microbiological risk to the patient. Material transfer can be a complex process dependent on material packaging, design of pass-through chamber, and method of bio-decontamination. Evaluating this risk holistically, from warehouse to Grade A is the key to ensuring microbiological control is robust. With both manual and automated bio-decontamination options available, each presents critical concerns that incorporate close assessment of operator behavior and equipment capability. This presentation will build on fundamental knowledge with case studies for reducing risks with material transfers.

2:10 Applying the ANSI-03 Quality Risk Management Standard—A Case Study



Noël Long, Senior Sterility Assurance Adviser, Cytiva

This talk walks through a real-life example of how the ANSI-03 standard can improve aseptic filling and low bioburden processing where contamination is a concern. Using the Swiss cheese analogy from the QRM standard, a team of microbiologists and engineers evaluated the layers of protection designed into a gloveless robotic isolator – from changeover and set-up through unloading of filled and closed vials. By providing a real-life example, the audience will gain familiarity with the standard and learn how the team adapted the method to evaluate and understand continuous improvement that is prioritized based on risk. The case study will show how ANSI-03 standardizes risk-based decision-making, enables team discussions, and provides a structured framework that supports proactive identification, assessment, and control of contamination risks. Attendees will leave with insights into the standard's core principles and how it aligns with global regulatory expectations

2:50 *Afternoon Coffee & Networking Break*

3:05

Transforming QRM for Faster Commercialization



Sebastian Scheler, Managing Director, Innerspace

Abstract Coming Soon

3:45


Close of Program



PharmaEd Resources, Inc. • 2810 Robeson Park Drive • Champaign, IL 61822

About Your Destination.

La Jolla, California, has enchanted generations of travelers. Follow in their footsteps and embark on an adventure like no other with a stay at Sheraton La Jolla Hotel. Famous attractions like Torrey Pines Golf Course, the San Diego Zoo, Balboa Park, LEGOLAND and the USS Midway are all nearby. Visit celebrated academic institutions such as Birch Aquarium and the University of California San Diego. Our La Jolla hotel also places you near local restaurants, breweries, distilleries and shops. If you prefer to relax at our hotel, we offer an oasis filled with palm trees, manicured gardens, cascading waterfalls and tranquil koi ponds. Stay fit in our hotel gym and heated outdoor pool. At night, savor tasty cuisine, inventive cocktails and live entertainment at our two on-site restaurants before you retire to your peaceful accommodations. See why La Jolla is called the "Jewel of San Diego."



Registration Information

Register for the conference using one of three options:

Online: www.pharmaedresources.com Phone: (217) 721-5774

Mail: 2810 Robeson Park Drive, Champaign, IL 61822

Please Complete the Following

FIRST NAME: _____

LAST NAME: _____

TITLE: _____

COMPANY: _____

ADDRESS: _____

ADDRESS: _____

CITY: _____ STATE: _____

ZIP: _____ COUNTRY CODE: _____

OFFICE PHONE: _____

MOBILE PHONE: _____

FAX: _____

E-MAIL: _____

VENUE INFORMATION:

Dates: **December 2-3, 2026**

Venue: **Sheraton La Jolla**

Venue Address: **3299 Holiday Court
La Jolla CA 92037**

Venue Phone: **(858) 453-5500**

Please register me for:

Aseptic Processing Summit 2026

Standard Registration	\$1,795
Early Bird Registration (by October 15 th)	\$1,595
Call for government, academic, or non-profit rate	

PAYMENT METHOD

CREDIT CARD REGISTRATION:

☐ CREDIT CARD ☐ VISA ☐ MASTERCARD ☐ AMEX

NAME: _____

CARD #: _____

EXPIRATION: ____ / ____

SIGNATURE: _____

BILLING ADDRESS: _____

CHECK REGISTRATION:

To pay by check, please provide a purchase order below. Please note that all payments must be received five (5) days prior to the conference to ensure space. Attendees will not be admitted to the conference without full payment.

PURCHASE ORDER #:

PLEASE NOTE:

PharmaEd Resources does not offer refunds. However, if you cannot attend after registering, we are happy to apply your registration fee to another PharmaEd Resources event, or transfer your registration to a colleague. Notice of cancellation must be received at least 5 days prior to the event.